Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
103 hedge funds and large institutions have $1.09B invested in Avidity Biosciences in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 19 closing their positions.
54,300% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $5K
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
10.07% more ownership
Funds ownership: 96.85% → 106.91% (+10%)
1% more capital invested
Capital invested by funds: $1.08B → $1.09B (+$5.92M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 107 → 103 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
+$64M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.01M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.31M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$23.8M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.04M |
| 3 |
FAM
Fred Alger Management
New York
|
-$2.55M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$2.12M |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
-$1.17M |
RNAM Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2022, worth a combined $1.09B — up 0.55% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RNAM and 15 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 34 added.
The largest buyer was Aaron Wealth Advisors, adding an estimated $64M. The largest seller was Deep Track Capital, exiting entirely with an estimated $23.8M sold.
- 103 institutional investors held Avidity Biosciences (RNAM) as of Q1 2022, down from 107 in Q4 2021.
- Funds reported $1.09B of Avidity Biosciences stock for Q1 2022, up 0.55% quarter-over-quarter.
- 15 funds opened new Avidity Biosciences positions in Q1 2022 and 19 closed out, a net change of -4 holders.
- The largest Avidity Biosciences buyer in Q1 2022 was Aaron Wealth Advisors, an estimated $64M added.
- The largest Avidity Biosciences seller in Q1 2022 was Deep Track Capital, an estimated $23.8M sold.
Based on aggregated 13F filings for Q1 2022.